Cellenkos CK0801 FDA Phase 2 Clearance
Analysis based on 7 articles · First reported Apr 27, 2026 · Last updated Apr 27, 2026
The FDA clearance for Cellenkos' CK0801 to enter Phase 2 clinical trials is a positive signal for the biotechnology sector, particularly for companies developing treatments for rare diseases. This advancement could lead to increased investor confidence in Cellenkos and similar clinical-stage companies, potentially boosting their valuations.
Cellenkos, a clinical-stage biotechnology company, announced that the United States — Food and Drug Administration has granted clearance to initiate a Phase 2 clinical trial for CK0801. CK0801 is an allogeneic cord blood-derived regulatory T cell (Treg) therapy designed to treat aplastic anemia, a rare and life-threatening blood disorder. The Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 in transfusion-dependent aplastic anemia patients. Previous Phase 1 trial outcomes showed a favorable safety profile and early signals of durable clinical activity, including transfusion independence in some patients. Simrit Parmar, Founder of Cellenkos, and Tara Sadeghi, Chief Operating Officer, emphasized the significant unmet medical need for aplastic anemia patients and the potential of CK0801 as a transformative therapy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard